Skip to main content Skip to main navigation menu Skip to site footer
Short communication
Austral J. Vet. Sci.
Vol 54, 23-28 (2022)
DOI: 10.4067/S0719-81322022000100023

Assessment of the CPL-0015 isolate as a vaccine strain for the control of canine parvovirus in Cuba

1 Empresa Productora de Vacunas Virales y Bacterianas. Grupo Empresarial LABIOFAM. Avenida Independencia km 16 ½, Boyeros, La Habana, Cuba.
2 Dirección de Investigación y Desarrollo. Grupo Empresarial LABIOFAM. Avenida Independencia km 16 ½, Boyeros, La Habana, Cuba.
3 Grupo de Investigación en Ciencia Animal, Universidad Cooperativa de Colombia, Bucaramanga, Colombia.
Keywords: canine parvovirus dogs safety protection vaccine

Submitted: 2021-07-27

Accepted: 2022-01-19

Published: 2022-05-06

*Corresponding author:
daniel.cala@campusucc.edu.co

How to Cite

Zayas, M. P., del T. Yen, Y. ., Naranjo, G. P., Odio, A. D., & Cala Delgado, D. L. (2022). Assessment of the CPL-0015 isolate as a vaccine strain for the control of canine parvovirus in Cuba. Austral Journal of Veterinary Sciences, 54(1), 23–28. https://doi.org/10.4067/S0719-81322022000100023

License

Copyright (c) 2022 Mayelin P. Zayas, Yenis del T. Yen, Gladys P. Naranjo, Aníbal D. Odio, Daniel L. Cala Delgado

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

The safety and protective efficacy of the CPL-0015 Cuban isolate of canine parvovirus type 2 (CPV-2) were evaluated for its possible use as a vaccine strain candidate. The study included a total of 23 healthy Beagle dogs of both sexes, aged 84 days and without specific maternal antibodies against canine parvovirus. Safety was analysed by comparing clinicopathological values, food consumption, body weight, rectal temperature and white blood cell counts for 14 consecutive days between control dogs (n=5) and dogs subcutaneously injected (n=10) with 2 mL (equivalent to two doses) of the CPL-0015 strain with an antigenic titer of 106.0 infectious dose50 in cell culture/mL. The protective effectiveness was determined by measuring and comparing anti-CPV-2 IgG levels and clinical signs during 56 experimental days between control dogs (n=2) and dogs inoculated (n=6) with double doses of 1 mL each, separated by a 21-day interval. All animals were challenged orally on day 35 with the virulent strain Cornell-780916 (105.0 infective dose50 in cell culture/mL). The results showed that the CPL-0015 strain did not negatively impact the physiological condition of the exposed animals. The inoculated and challenged animals showed not only significantly increased levels of anti-CPV-2 IgG (P<0.05) when compared to days 0, 35, and the control group animals but also had 100% survival without clinical signs of the disease, unlike the control group. It is concluded that CPL-0015 is safe and provides effective protection against homologous virulent strains.

Downloads

Download data is not yet available.

References

  1. Altman KD, Kelman M, Ward MP. 2017. Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure? Vet Microbiol 210, 8-16.
  2. Aponte FA, Gómez RV, López YM. 2020. Factores predisponentes a la parvovirosis canina registrados en un hospital de Cuautitlan, México. Rev Vet 31, 42-45.
  3. Cunegündes GM, Gomes AL, Viana BF, Paes LH, Shimoya Aldo, et al. 2008. Production and use of egg-yolk antibody for detection of canine parvovirus in feces. Rev Cin Méd Biol 7, 241-248.
  4. Day M. 2008. Vaccine side effects: Fact and fiction. Vet Microbiol 117, 51-58.
  5. De Cramer KG, Stylianides E, Van Vuuren M. 2011. Efficacy of vaccination at 4 and 6 weeks in the control of parvovirus canine. Vet Microbiol 149, 126-132.
  6. Decaro N, Buonavoglia C, Barrs VR. 2020. Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication? Vet Microbiol 247, 108760.
  7. Díaz C, Correa J, Vera V. 2008. Aspectos moleculares del virus de la parvovirosis canina y sus implicaciones en la enfermedad. Rev Med Vet 15, 57-65.
  8. Domínguez OA, Acosta DP, Oliva LM, Rosales BK. 2021. Vacuna cubana contra Pasteurella multocida cunícula: 52 años de inmunización. Rev Salud Anim 43, 1-3.
  9. Domínguez OA, Polanco R, Cossío G, Morejón Y, Riquenes Y. 2014. Current trends and perspectives in veterinary vaccine production. Biotec Apl 31, 196-203.
  10. Dong B, Zhang G, Zhang J, Bai J, Lin W. 2020. A systematic literature review and meta-analysis of characterization of canine parvoviruses 2 prevalent in mainland China. Virol J 17, 1-10.
  11. Fresneda A, Contreras D, Paneque M, de la Cruz L, Veda C. 2015. Caracterización molecular de un aislamiento cubano de parvovirus canino. VacciMonitor 24, 113-119.
  12. Hao X, He Y, Wang C, Xiao W, Liu R, et al. 2020. The increasing prevalence of CPV-2c in domestic dogs in China. Peer J 8, e9869.
  13. Hernández BB, Catala LF. 2015. Are licensed canine parvovirus (CPV2 and CPV2b) vaccines able to elicit protection against CPV2c subtype in puppies?: a systematic review of controlled clinical trials. Vet Microbiol 180, 1-9.
  14. Khatri R, Poonam MH, Minakshi CS. 2017. Epidemiology, pathogenesis, diagnosis and treatment of canine parvovirus disease in dogs: A mini review abstract. J Vet Sci Med Diagn 6, 2.
  15. Langeveld PJ, Brennan RF, Martínez TJ, Jones DT, Boshuizen SR, et al. 2001. Inactivated recombinant plant virus protects dogs from a lethal challenge with canine parvovirus Vaccine 19, 3661-3670.
  16. Larson LJ, Schultz RD. 2008. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant. Vet Ther 9, 94-101.
  17. Li G, Ji S, Zhai X, Zhang Y, Liu J, et al. 2017. Evolutionary and genetic analysis of the VP2 gene of canine parvovirus. BMC Genomics 18, 1-13.
  18. Lugo S, Espinosa C, Zamora B, Riera O, Sosa T, et al. 2019. Caracterización microbiológica y genotípica de cepas de Pasteurella multocida asociadas al síndrome respiratorio cunícula. Rev Salud Anim 41, 1-11.
  19. Meunier PC, Cooper BJ, Appel MJ, Lanieu ME, Slauson DO. 1985. Pathogenesis of canine parvovirus enteritis: sequential virus distribution and passive inmunization studies. Vet Pathol 22, 617-624.
  20. Miranda C, Thompson G. 2016. Canine parvovirus: the worldwide occurrence of antigenic variants. J Gen Virol 97, 2043-2057.
  21. Moore G, Hogen E. 2010. Adverse vaccinal events in dogs and cats. Vet Clin Smal Anim 40, 393-407.
  22. Mukthar M, Hasan M. 2021. Update on canine parvovirus infection: a review from the literature. Vet Sc Res Rev 7, 92-100.
  23. Oliveira HS, Geraldes PF, Lopes RJ, D’Ávila VG, Fischer G, et al. 2010. Exposure of pampas fox (Pseudalopex gymnocercus) and crab-eating fox (Cerdocyon thous) from the Southern region of Brazil to canine distemper virus (CDV), canine parvovirus (CPV) and canine coronavirus (CCoV). Braz Arch Biol Technol 53, 593-597.
  24. Peña GI, Vidal FF, Hernández RA. 2020. Factores de riesgo de la parvovirosis canina en cuatro localidades de Cuba. Rev Inv Vet Perú 31, e17824.
  25. Pino RD, Márquez AM, Torres GC, Matos RR, Zamora MY. 2019. Factores de riesgo asociados a la seroprevalencia de parvovirus canino en perros del municipio Boyeros, La Habana, Cuba. Rev Salud Anim 41, 1-6.
  26. Pratelli A, Cavalli A, Martella V, Tempesta M, Decaro N, et al. 2001. Canine parvovirus vaccination: comparison of neutralising antibody responses in pups after inoculation with CPV2 or CPV2b modified live virus vaccines. Clin Diag Lab Immunol 8, 612-615.
  27. Puentes PR. 2012. Parvovirosis canina: situación actual y protección de las vacunas contra las nuevas variantes virales circulantes en la región. Vet 48, 5-10.
  28. Puentes RR, Eliopulos N, Pérez R, Franco G, Sosa K, et al. 2012. Isolation and characterization of canine parvovirus type 2c (CPV-2c) from symptomatic puppies. Braz J Microb 1005-1009.
  29. Qi S, Zhao J, Guo D, Sun D. 2020. A Mini-Review on the epidemiology of canine parvovirus in China. Front Vet Sci 7, 5-11.
  30. Sebastian BP, Felipetto CJ, Kenji ME, Weiblen R, Furtado FE. 2019. New variants of canine parvovirus in dogs in southern Brazil. Arch Virol 164, 1361-1369.
  31. Siedek EM, Schmidt H, Sture GH, Raue R. 2011. Vaccination with canine parvovirus type 2 (CPV-2) protects against challenge with virulent CPV-2b and CPV-2c. Berl Munch Tierarztl Wochenschr 124, 58-64.
  32. Spibey N, Greenwood N, Sutton D, Chalmers W, Tarpey I. 2008. Canine parvovirus type 2 protects against virulent challenge with type 2c virus. Vet Microbiol 128, 48-25.
  33. Voorhees IE, Lee H, Allison AB, Lopez-Astacio R, Goodman LB, et al. 2019. Limited intrahost diversity and background evolution accompany 40 years of canine parvovirus host adaptation and spread. J Virol 94, e01162-19.
  34. Wilson S, Stirling C, Borowski S, Thomas A, King V, et al. 2013. Vaccination of dogs with Duramune DAPPi+LC protects against pathogenic canine parvovirus type 2c challenge. Vet Rec 172, 662-672.
  35. Ying EY, Peaston A, Woolford L, Khuu SJ, Wallace G, et al. 2020. Diagnostic challenges in canine parvovirus 2c in vaccine failure cases. Viruses 12, 980-93.
  36. Zhou P, Zeng W, Zhang X, Li S. 2017. The genetic evolution of canine parvovirus-A new perspective. PLoS ONE 12, e0175035.
  37. Zhuang QY, Qiu Y, Pan ZH. 2019. Genome sequence characterization of canine parvoviruses prevalent in the Sichuan province of China. Transbound Emerg Dis 66, 897–907.

Make a Submission

Make a Submission

Journal Metrics (2023) & Ranking

Impact Factor
→
0.5 (2024)
5 years Impact Factor
→
0.8
JCR Quartile
→
Q4
JIF Rank
→
134/170 (Veterinary Sciences)
SJR (2024)
→
0.244
SNIP (2024)
→
0.35

 

 

SCImago Journal & Country Rank

Indexed in

Publisher


This journal is published by the Facultad de Ciencias Veterinarias, Universidad Austral de Chile

Keywords